Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Review Article

Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders

Author(s): Ana M. Garcia, Ana Martinez and Carmen Gil

Volume 16, Issue 29, 2016

Page: [3527 - 3535] Pages: 9

DOI: 10.2174/1568026616666160426151306

Price: $65

Abstract

Phosphodiesterases (PDEs) have gained attention as potential pharmacological targets for neuropsychiatric diseases due to their ability to hydrolyze the second messengers, cGMP and/or cAMP. It is well-known the relationship between cAMP signaling and inflammation. Since neuroinflammation is considered to play an important role in the pathology of brain disorders, inhibition of PDEs highly expressed in brain has emerged as an innovative strategy for the treatment of these pathologies. PDE4, 7, 8 and 10 inhibitors are presented here as promising drug candidates to overcome the partial efficacy and adverse effects of the current therapy for neuropsychiatric illness such as depression, cognitive impairments or schizophrenia. Enhancing the intracellular concentration of cAMP underlies the effects of PDE inhibitors in the above mentioned disorders.

Keywords: cAMP, Cognitive Impairment, Depression, Phosphodiesterase, inhibitors, Schizophrenia.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy